Northwest Bancshares Inc. Has $441,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Northwest Bancshares Inc. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,370 shares of the medical research company’s stock after selling 106 shares during the period. Northwest Bancshares Inc.’s holdings in Amgen were worth $441,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in Amgen in the third quarter valued at about $25,000. Hershey Financial Advisers LLC acquired a new stake in Amgen during the second quarter valued at approximately $30,000. nVerses Capital LLC bought a new stake in shares of Amgen in the 2nd quarter valued at approximately $31,000. Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter worth approximately $33,000. Finally, Matrix Trust Co bought a new position in shares of Amgen during the 3rd quarter worth approximately $36,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMGN. Sanford C. Bernstein initiated coverage on Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective for the company. Wolfe Research initiated coverage on shares of Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Truist Financial lowered shares of Amgen from a “buy” rating to a “hold” rating and raised their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Barclays increased their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Finally, StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average target price of $333.57.

Amgen Trading Up 0.4 %

NASDAQ:AMGN opened at $279.95 on Wednesday. The firm has a market capitalization of $150.48 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85. The business’s 50-day moving average price is $318.92 and its two-hundred day moving average price is $318.43. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter last year, the firm earned $4.96 EPS. Amgen’s quarterly revenue was up 23.2% compared to the same quarter last year. On average, equities analysts expect that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.